- GlobeNewswire•26 minutes ago
BARDA Grants $43.2 million USD to Sanofi Pasteur for Zika - Funds will be used for phase II development and manufacturing - Paris, France - September 26, 2016 - Sanofi and its vaccines global business ...
- Zacks•2 hours ago
Intelligent care is where modern medicine seems to be headed with pharma and tech companies collaborating for better healthcare solutions.
- American City Business Journals•4 hours ago
The second of two potential drugs for immune system disorders that are together expected to bring in peak annual revenues of between $3 billion and $7 billion to Sanofi Genzyme and a New York based partner in the next few years is expected to have a decision on U.S. approval by next spring. Both drugs are partnered between the Cambridge-based division of Sanofi (SNY) that’s focused on specialty pharmaceuticals (formerly called simply Genzyme), and Tarrytown, N.Y.-based Regeneron Pharmaceuticals (REGN). Both are also biologics (protein-based) and while they weren’t developed in Cambridge, they will be marketed by Sanofi Genzyme under a reorganization of the parent company announced more than a year ago.
Paris - Paris Delayed Price. Currency in EUR
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||67.39 - 68.17|
|52wk Range||24.83 - 93.82|
|1y Target Est||N/A|
|P/E Ratio (ttm)||21.05|
|Avg Vol (3m)||9,830|
|Dividend & Yield||N/A (N/A)|